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Regulation of cell proliferation by ion channels in human mesenchymal stem cells
YY Zhang, HF Tse, CP Lau, GR Li
Department of Medicine, The University of Hong Kong, Hong Kong
Introduction: Human bone marrow–derived mesenchymal stem cells (hMSCs) are a promising cell source for 
regenerative medicine; however, cellular physiology is not fully understood in hMSCs. The present study was 
to determine the potential role of the dominant functional ion channels, large-conductance Ca2+-activated 
K+ (BKCa) channel, human ether-à-go-go K+ (hEAG1) channel, and Na+ channel, in regulating proliferation of 
hMSCs.
Methods: Ionic currents were recorded using a whole-cell patch-clamp technique. Cell proliferation assay was 
made with MTT and 3H-thymidine incorporation approaches. Cell cycle distribution was determined by flow 
cytometry.
Results: We found that the BKCa channel blocker paxilline (1 µM) almost fully inhibited BKCa current (from 
6.76±0.99 pA/pF of control, to 0.02±0.09 pA/pF at +100 mV, n=5, P<0.05) in hMSCs. The hEAG1 channel blocker 
astemizole (0.5 µM) significantly reduced hEAG1 current from 4.28±1.86 pA/pF to 1.40±1.13 pA/pF at +50 mV, 
n=6, P<0.05). The MTT experiment showed that paxilline at 0.3, 1.0, and 3.0 µM reduced cell proliferation to 
97.2, 84.4, and 48.7% of control, respectively, and astemizole at 0.3, 0.5, and 1 µM decreased cell proliferation 
to 96.5, 80.5, and 45.8%, respectively. However, the Na+ channel blocker tetrodotoxin (1 µM, fully blocked Na+ 
current) had no effect on proliferation in hMSCs. Both paxilline and astemizole reduced DNA synthesis rate 
in a concentration-dependent manner. Inhibition of BKCa channel with 1 µM paxilline or hEAG1 channel with 
0.5 µM astemizole accumulated cells at G0/G1 phase (from control 68.9% to 80.5% for paxilline; to 79.2% for 
astemizole).
Conclusion: Our results demonstrate that BKCa and hEAG1 channels, but not Na+ channel, participate in the 
regulation of cell proliferation by promoting G0/G1 cells into cell cycling progression.
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114Human embryonic stem cells–derived mesenchymal stem cells functionally attenuate 
monocrotaline-induced pulmonary arterial hypertension in mice
YL Zhang, QZ Lian, Y Zhang, SR Kang, SY Liao, XG Wu, YY Chow, HF Tse
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Introduction: Transplantation of bone marrow (BM)–derived mesenchymal stem cells (MSCs) has been shown to 
attenuate pulmonary arterial hypertension (PAH). However, the effect of human embryonic stem cells (hESCs)–
derived MSC which may have higher proliferative capacity than BM-MSCs on the pulmonary vascular bed in 
monocrotaline (MCT)-induced animal model of PAH has not been determined. In the present study, the effects 
of hESC-MSCs versus BM-MSCs transplantation on MCT-induced pulmonary arterial hypertension (PAH) were 
compared in mice.
Methods: PAH was induced in adult mice (ICR strain) by intraperitoneal injection of 400 mg/kg MCT. As the 
negative control, mice received saline instead of MCT (control group, n=6). One week after MCT administration, 
the animals were randomised to receive intravenous administration of: (1) PBS (MCT group, n=6); (2) 3.0x106 
BM-MSCs (BMC group, n=6); or (3) 3.0x106 hESC-MSCs (hESC group, n=6) via tail vein. All animals were 
treated with cyclosporine (15 mg/kg) daily after transplantation. Invasive haemodynamic assessment and 
immunohistological studies were performed at 3 weeks after transplantation.
Results: Administration of either hESC-MSCs or BM-MSCs significantly attenuated elevated RV systolic pressure 
and reduced RV hypertrophy. After 1 week of transplantation, both hESC-MSCs and BM-MSCs not only retained 
in the wall of pulmonary vessels and in lung parenchyma, but also underwent vascular differentiation and 
cytokine release. However, after 3 weeks of transplantation, both BM-MSCs and hES-MSCs were undetectable 
in lung tissues as confirmed by immunostaining for human nuclear antigen (HNA) and PCR. Both hESC-MSCs 
and BM-MSCs were able to reduce microvascular wall thickness and increase density of pulmonary capillary to 
augment MCT-induced PAH.
Conclusion: We conclude hESC-MSCs are as functional as BM-MSCs to attenuate MCT-induced PAH. Despite 
hESC-MSCs have a higher proliferative capacity, both cell types are poor to long-term survive well in injured 
lung environments.
